Therapeutic Options in Hormone Refractory Prostate Cancer

  • A. Heidenreich

Abstract

Adenocarcinoma of the prostate is the most prevalent tumor in men, a major cause of morbidity and mortality mainly because of the hormone refractory component. Hormone refractory prostate cancer (HRPCA) causes about 42,000 deaths annually [58, 98].

Keywords

Paclitaxel Warfarin Doxorubicin Cyclophosphamide Prednisone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albrecht W, Horenblas S, Marechal JM, Mikisch G, Horwich A, Seretta V, Cassetta G, van Poppel H, Kalman S, Sylvester R (1998) EMP versus EMP/VBL Chemotherapie beim hormonrefraktären Prostatakarzinom. Urologe A 37:32Google Scholar
  2. 2.
    Benson R, Hartley-Asp B (1990) Mechanisms of action and clinical uses of estramustine. Cancer Invest 8:375PubMedCrossRefGoogle Scholar
  3. 3.
    Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA. Jr (1993) Doxorubicin, mitomycin C and 5-flourouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J Urol 150:411–413PubMedGoogle Scholar
  4. 4.
    Breul J, Paul R (1998) Das Antiandrogen-Entzugssyndrom. Urologe A 37:156–158PubMedCrossRefGoogle Scholar
  5. 5.
    Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467PubMedGoogle Scholar
  6. 6.
    Crawford ED, Rosenblum M, Ziada AM, Lange PH. (1999) Overview: hormone refractory prostate cancer. Urology 54 [Suppl 6A]:1–7PubMedCrossRefGoogle Scholar
  7. 7.
    Culine S, Kattan J, Zanetta S, Theodore C, Fizazi K, Droz JP. (1998) Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol 21:470–474PubMedCrossRefGoogle Scholar
  8. 8.
    DeLa Taille A, Hayek OR, Buttyan R, et al (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: preliminary investigation on human cell lines and patients. Br J Urol 84: 845–850Google Scholar
  9. 9.
    DeLa Taille A, Buttyan R, Hayek O, et al (2000) Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164:1229–1234PubMedCrossRefGoogle Scholar
  10. 10.
    Denis L (1998) European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976-1996. Urology 51 [Suppl 5A]:50–57PubMedCrossRefGoogle Scholar
  11. 11.
    De Voogt HJ, Sucuiu S, Sylvester R (1989) Univariate analysis of prognostic factors in patients with advanced prostatic carcinoma: results from two European organizations for research on treatment of cancer trials. J Urol 141:883–888PubMedGoogle Scholar
  12. 12.
    Dijkman GA, van Moorseiaar RJ, van Ginckel R, van Stratum P, Wouters L, Debruyne F, Schalken JA, de Coster R (1994) Antitumoral effects of liarozole in in androgen dependent and independent prostate cancer. J Urol 151:217–222PubMedGoogle Scholar
  13. 13.
    DiPaola RS, Zhang H, Lambert GH, et al (1998) Clinical and biologic activity of an estrogen herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339:785–791CrossRefGoogle Scholar
  14. 14.
    Dowsett M, Shearer RJ, Ponder B.A.J, et al (1988) The effects of aminogluthetimide and hydrocortisone, alone and combined, on androgen levels in prost-orchiectomy prostate cancer patients. Br J Cancer 57:190–192PubMedCrossRefGoogle Scholar
  15. 15.
    Dupont A, Gomez JL, Cusan L, Koutselieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908–913PubMedGoogle Scholar
  16. 16.
    Ellerhorst JS, Tu SM, Amato RJ. (1997) A phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371PubMedGoogle Scholar
  17. 17.
    Falcone A, Antonuzzo A, Danesi R, Allegrini G, Monica L, Pfanner E, Masi G, Ricci S, Del Tacca M, Conte P (1999) Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 86:470–476PubMedCrossRefGoogle Scholar
  18. 18.
    Figg WD, Sartor O, Cooper MR. (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412–414PubMedCrossRefGoogle Scholar
  19. 19.
    Fowler JE, Pandey P, Seaver LE, et al (1995) Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 154:448–453PubMedCrossRefGoogle Scholar
  20. 20.
    Friedland D, Cohen J, Miller R, Gluckamn R, Zidar B, Lembersky B, Keating M, Voloshin M, Balaban E, Pinkerton R, Reilly N, Dimitt P, Kinney C (1999) A phase II trial in hormone refractory prostate cancer: correlation of antitumor activity to phosphorylation of bcl-2. Proc Am Soc Clin Oncol 18:322aGoogle Scholar
  21. 21.
    George DJ, Kanthoff PW. (1999) Prognostic indicators in hormone refractory prostate cancer. Urol Clin North Am 26:303–309PubMedCrossRefGoogle Scholar
  22. 22.
    Ghossein RA, Rosai J, Scher HI. (1997) Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50:100–105PubMedCrossRefGoogle Scholar
  23. 23.
    Gomella LG, Ismail M, Nathan FE. (1997) Antiandrogen withdrawal syndrome with nilutamide. J Urol 157:1366PubMedCrossRefGoogle Scholar
  24. 24.
    Graefen M, Hammerer P, Haese A, Huland H (2000) Therapieoptionen des hormonrefraktaren Prostatakarzinoms. Urologe A 39:267–273PubMedCrossRefGoogle Scholar
  25. 25.
    Haldar S, Basu A, Croce CM. (1996) Bcl-2 is the guardian of the microtubule. Cancer Res 2:389–395Google Scholar
  26. 26.
    Hartley-Asp B, Kruse E (1986) Nuclear protein matrix as a target for estramustine induced cell death. Prostate 9:387PubMedCrossRefGoogle Scholar
  27. 27.
    Herrada J, Dieringer P, Logothetis CJ. (1996) Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996; 155:620–623PubMedCrossRefGoogle Scholar
  28. 28.
    Heidenreich A, Engelmann UH, Hofmann R (2001) The use of bisphosphonates for the palliative treatment of painful bone metastases due to hormone refractory prostate cancer. J Urol 165:136–140PubMedCrossRefGoogle Scholar
  29. 29.
    Huan SD, Gerridzen RG, Yau JC, et al (1997) Antiandrogen withdrawal syndrome with nilutamide. Urology 49:632–634PubMedCrossRefGoogle Scholar
  30. 30.
    Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. (1999) Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 22:471–474PubMedCrossRefGoogle Scholar
  31. 31.
    Hubert A, Lyass O, Pode D, Gabizon A (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123–127PubMedCrossRefGoogle Scholar
  32. 32.
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B (1999) Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17:3160–3166PubMedGoogle Scholar
  33. 33.
    Hudes GR, Nathan F, Khater C (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin Oncol 15:3156PubMedGoogle Scholar
  34. 34.
    Hussain M, Wolf M, Marshall E, et al (1994) Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group Report. J Clin Oncol 12:1868–1875PubMedGoogle Scholar
  35. 35.
    Isaacs JT. (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26:263–273PubMedCrossRefGoogle Scholar
  36. 36.
    Johnson DE, Babaian RJ, von Eschenbach AC, et al (1988) Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 31:132–134PubMedCrossRefGoogle Scholar
  37. 37.
    Joyce R, Fenton MA, Rode P, et al (1998) High dose biclutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159:149–153PubMedCrossRefGoogle Scholar
  38. 38.
    Kanthoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17:2506–2513Google Scholar
  39. 39.
    Kelly WK, Scher H (1993) Prostate specific antigen decline after androgen withdrawal syndrome. J Urol 149:607–613PubMedGoogle Scholar
  40. 40.
    Kelly WK, Curley T, Leibertz C, et al (1995) Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208–2213PubMedGoogle Scholar
  41. 41.
    Kelly WK, Scher HI, Mazumdar M (1995) Suramin and hydrocortisone: determining the efficacy in androgen-independent prostate cancer. J Clin Oncol 13:2214PubMedGoogle Scholar
  42. 42.
    Klotz L, McNeill I, Fleshner N (1999) A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 161:169–172PubMedCrossRefGoogle Scholar
  43. 43.
    Kluog RC, Farah RN, Cerny JC. (1981) Bilateral orchiectomy for carcinoma of the prostate: response of serum testosterone and clinical response to estrogen therapy. Urology 17:49–54CrossRefGoogle Scholar
  44. 44.
    Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38PubMedCrossRefGoogle Scholar
  45. 45.
    Laurie JA, Hahn RG, Therneau TM. (1992) Chemotherapy for hormonally refractory advanced prostate carcinoma: a comparison of combined versus sequential treatment with mitomycin C, doxorubicin and 5-flou-rouracil. Cancer 69:1440PubMedCrossRefGoogle Scholar
  46. 46.
    Logothetis CJ, Samuels ML, von Eschenbach AC. (1983) Doxorubicin, mitomycin C and 5-flourouracil in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol 1:368PubMedGoogle Scholar
  47. 47.
    Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hersey D, Gordon R, Rohner T, Drago J, Wettlaufer J, Glode L (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6:1456–1466PubMedGoogle Scholar
  48. 48.
    Miglietta L, Canobbio L, Grabetto C, Vannozzi MO, Esposito M, Boccardo F (1997) Suramin/ epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 123:407–410PubMedGoogle Scholar
  49. 49.
    Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689–694PubMedGoogle Scholar
  50. 50.
    Murphy GP. (1999) Review of phase II hormone refractory prostate cancer trials. Urology 54 [Suppl 6A]:19–21PubMedCrossRefGoogle Scholar
  51. 51.
    Myers CE, Cooper MR, Stein C (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881PubMedGoogle Scholar
  52. 52.
    Navone NM, Troncoso P, Pisters LL, et al (1993) P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657–1663PubMedCrossRefGoogle Scholar
  53. 53.
    Newling DW, Dennis L, Vermeylen K (1993) Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 72:3793–3798PubMedCrossRefGoogle Scholar
  54. 54.
    Nieh PT. (1995) Withdrawal phenomenon with the antiandrogen Casodex. J Urol 153:1070–1073PubMedCrossRefGoogle Scholar
  55. 55.
    Ornstein DK, Smith DS, Andriole GL. (1998) Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology 52:1094–1097PubMedCrossRefGoogle Scholar
  56. 56.
    Osborne CK, Blumenstein BA, Crawford ED, Weiss GR, Bukowski RM, Larrimer NR. (1992) Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group study. Eur J Cancer 28:477–478PubMedCrossRefGoogle Scholar
  57. 57.
    Osoba D, Tannock IF, Ernst SD, Neville AJ. (1999) Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654–1663PubMedGoogle Scholar
  58. 58.
    Parker SL, Tong T, Bolden S, Wingo PA. (1996) Cancer statistics, 1997. CA Cancer J Clin 46:5–27CrossRefGoogle Scholar
  59. 59.
    Petrylak DP. (1999) Chemotherapy for advanced hormone refractory prostate cancer. Urology 54 [Suppl 6A] 31–35CrossRefGoogle Scholar
  60. 60.
    Petrylak DP, Macarthur RB, O’Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA. (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958–967PubMedGoogle Scholar
  61. 61.
    Pienta KJ, Redman B, Hussain M (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005–2012PubMedGoogle Scholar
  62. 62.
    Pienta KJ, Esper PS, Smith DC. (1997) The oral regimen of Cytoxan, prednisone, and diethylbestrol is an active, non-toxic treatment for patients with hormone refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol 16:1104Google Scholar
  63. 63.
    Pienta KJ, Redman BG, Bandekar R, Strawderman MA, Cease K, Esper PS, Naik H, Smith DC. (1997) A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50:401–407PubMedCrossRefGoogle Scholar
  64. 64.
    Plowman PN, Perry LA, Chard T (1987) Androgen suppression by hydrocortisone without aminogluthetmide in orchiectomised men with prostatic cancer. Br J Urol 59:255–257PubMedCrossRefGoogle Scholar
  65. 65.
    Presti JC. (1999) The role of the urologist in adjuvant chemotherapy trials for prostate cancer. Urology 54 [Suppl 6A]:47–50PubMedCrossRefGoogle Scholar
  66. 66.
    Reese DM, Small EJ. (1999) Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am 26:311–319PubMedCrossRefGoogle Scholar
  67. 67.
    Richie JP. (1999) Anti-androgens and other hormonal therapies for prostate cancer. Urol Clin North Am 26:15–18CrossRefGoogle Scholar
  68. 68.
    Sartor O, Cooper M, Weinberger M, et al (1994) Surprising activity of flutamide withdrawal, when combined with aminogluthetimide, in treatment of “hormone-refractory” prostate cancer. J Natl Cancer Inst 86:222–227PubMedCrossRefGoogle Scholar
  69. 69.
    Schellhammer P, Venner P, Haas G (1997) Prostate specific antigen decreases after withdrawal of antiandrogen therapy with biclutamid or flutamide in patients receiving combined androgen blockade. J Urol 157:1731–1735PubMedCrossRefGoogle Scholar
  70. 70.
    Scher H, Steinneck G, Kelly WK. (1995) Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46:142–148PubMedCrossRefGoogle Scholar
  71. 71.
    Scher H, Liebertz C, Kelly WK, et al (1997) Biclutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15:2928–2938PubMedGoogle Scholar
  72. 72.
    Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T (1992) Estramustine and vinblastine: use of prostate specific antigen as a clinical trial and point for hormone refractory prostatic cancer. J Urol 147:931–934PubMedGoogle Scholar
  73. 73.
    Seidmon EJ, Trump DL, Kreis W, et al (1995) Phase I/II dose-escalation study of liarazole in patients with stage D hormone-refractory carcinoma of the prostate. Ann Surg Oncol 2:550–556PubMedCrossRefGoogle Scholar
  74. 74.
    Sella A, Kilbourn R, Amato R (1994) Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol 12:683PubMedGoogle Scholar
  75. 75.
    Sinibaldi VJ, Carduci MA, Moore-Cooper S, Enger C, Laufer M, Wolff C, Eisenberger MA. (1999) A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 18:322aGoogle Scholar
  76. 76.
    Small EJ, Carroll PR. (1994) Prostate specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408–410PubMedCrossRefGoogle Scholar
  77. 77.
    Small EJ, Srinivas S (1995) The antiandrogen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428–1434PubMedCrossRefGoogle Scholar
  78. 78.
    Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. (1996) Doxorubicin and dose-escalating cyclophophamide with granulocyte colony-stimulating factor for the treatment of hormoneresistant prostate cancer. J Clin Oncol 14:1617–1625PubMedGoogle Scholar
  79. 79.
    Small EJ, Baron AD, Fippin L, et al (1997) Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204–1207PubMedCrossRefGoogle Scholar
  80. 80.
    Small EJ, Baron AD, Bok R, et al (1997) Simultaneous anitandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755–1759PubMedCrossRefGoogle Scholar
  81. 81.
    Small EJ, Frohlich MW, Bok R, et al (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595–3603PubMedGoogle Scholar
  82. 82.
    Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichemeyer WJ, Eisenberger M (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440–1450PubMedGoogle Scholar
  83. 83.
    Smith DC, Dunn RL, Strawderman MS, Pienta KJ. (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835–1843PubMedGoogle Scholar
  84. 84.
    Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. (1998) A phase II trial of oral diethylbestrol as a second line hormonal agent in advanced prostate cancer. Urology 52:257–260PubMedCrossRefGoogle Scholar
  85. 85.
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664–1671PubMedGoogle Scholar
  86. 86.
    Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933–941PubMedCrossRefGoogle Scholar
  87. 87.
    Tannock IF, Gospodarowicz M, Meakin W, et al (1989) Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597PubMedGoogle Scholar
  88. 88.
    Tannock IF, Osoba D, Stockier MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin C.M.L, Murphy KC. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764PubMedGoogle Scholar
  89. 89.
    Taplin ME, Bubley GJ, Shuster TD, et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398PubMedCrossRefGoogle Scholar
  90. 90.
    Taylor CD, Elson P, Trump DL. (1993) Importance of continued testicular suppression in hormone refractory prostate cancer. J Clin Oncol 11:2167–2172PubMedGoogle Scholar
  91. 91.
    Tew KD, Stearns ME. (1987) Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 15:155PubMedCrossRefGoogle Scholar
  92. 92.
    Tilley WD, Buchanan G, Hickey TE, et al (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277–285PubMedGoogle Scholar
  93. 93.
    Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478–1484PubMedCrossRefGoogle Scholar
  94. 94.
    Veronesi A, Re GL, Foladore S, Merlo A, Giuliotto N, Talamini R, Monfradini S (1996) Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North Eastern Italian Oncology Group. Eur Urol 29:434–438PubMedGoogle Scholar
  95. 95.
    Visakorpi T, Hyytinen E, Kovisto P, et al (1995) In vivo amplification of the androgen receptor and progression of prostate cancer. Nat Genet 9:401–409PubMedCrossRefGoogle Scholar
  96. 96.
    Vogelzang NJ, Crawford ED, Zietman A (1998) Current clinical trial design issues in hormonerefractory prostate cancer. Cancer 82:2093–2101PubMedCrossRefGoogle Scholar
  97. 97.
    Weitzman A, Shelton G, Zuech N, Englnad-Owen C, Newhouse J, Bagiella E, Katz A, Sawczuk I, Benson M, Olsson C, Petrylak DP. (1999) Phase II study of estramustine combined with docetaxel in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 18:355aGoogle Scholar
  98. 98.
    Wingo PA, Landis S, Ries L.A.G. (1997) An adjustment to the 1997 estimate for new prostate cancer. CA Cancer J Clin 47:239–242PubMedCrossRefGoogle Scholar
  99. 99.
    Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1098–1109Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • A. Heidenreich

There are no affiliations available

Personalised recommendations